{"pmid":32330314,"title":"Is BCG vaccination effecting the spread and severity of COVID-19?","text":["Is BCG vaccination effecting the spread and severity of COVID-19?","Allergy","Ozdemir, Cevdet","Kucuksezer, Umut C","Tamay, Zeynep Ulker","32330314"],"journal":"Allergy","authors":["Ozdemir, Cevdet","Kucuksezer, Umut C","Tamay, Zeynep Ulker"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330314","week":"202017|Apr 20 - Apr 26","doi":"10.1111/all.14344","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664996914776506368,"score":8.518259,"similar":[{"pmid":32295694,"title":"COVID-19 vaccination clinical trials should consider multiple doses of BCG.","text":["COVID-19 vaccination clinical trials should consider multiple doses of BCG.","Pharmazie","Ayoub, B M","32295694"],"journal":"Pharmazie","authors":["Ayoub, B M"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295694","week":"202016|Apr 13 - Apr 19","doi":"10.1691/ph.2020.0444","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664641388293128192,"score":87.09547},{"pmid":32300370,"pmcid":"PMC7148425","title":"Can an effective SARS-CoV-2 vaccine be developed for the older population?","text":["Can an effective SARS-CoV-2 vaccine be developed for the older population?","The emergence of SARS-CoV-2 and its inordinately rapid spread is posing severe challenges to the wellbeing of millions of people worldwide, health care systems and the global economy. While many younger people experience no or mild symptoms on infection, older adults are highly susceptible to life-threatening respiratory and systemic conditions which demand a full understanding and leveraging of knowledge of the differences between immunity in young and old people. Consequently, we welcome papers addressing any issues relevant to immunity and ageing in the context of SARS-CoV-2, and will endeavour to fast-track peer-review. We aim to provide a platform exclusively for discussions of individual and age differences in susceptibility and immune responses to COVID caused by SARS-CoV-2 infection and how to prevent or reduce severity of disease in older adults.","Immun Ageing","Pawelec, Graham","Weng, Nan-Ping","32300370"],"abstract":["The emergence of SARS-CoV-2 and its inordinately rapid spread is posing severe challenges to the wellbeing of millions of people worldwide, health care systems and the global economy. While many younger people experience no or mild symptoms on infection, older adults are highly susceptible to life-threatening respiratory and systemic conditions which demand a full understanding and leveraging of knowledge of the differences between immunity in young and old people. Consequently, we welcome papers addressing any issues relevant to immunity and ageing in the context of SARS-CoV-2, and will endeavour to fast-track peer-review. We aim to provide a platform exclusively for discussions of individual and age differences in susceptibility and immune responses to COVID caused by SARS-CoV-2 infection and how to prevent or reduce severity of disease in older adults."],"journal":"Immun Ageing","authors":["Pawelec, Graham","Weng, Nan-Ping"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300370","week":"202016|Apr 13 - Apr 19","doi":"10.1186/s12979-020-00180-2","keywords":["covid","immunosenescence","sars-cov-2","severe acute respiratory syndrome","vaccination"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664635401354084353,"score":48.018524},{"pmid":32290839,"pmcid":"PMC7154566","title":"Why tocilizumab could be an effective treatment for severe COVID-19?","text":["Why tocilizumab could be an effective treatment for severe COVID-19?","A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.","J Transl Med","Fu, Binqing","Xu, Xiaoling","Wei, Haiming","32290839"],"abstract":["A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality."],"journal":"J Transl Med","authors":["Fu, Binqing","Xu, Xiaoling","Wei, Haiming"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290839","week":"202016|Apr 13 - Apr 19","doi":"10.1186/s12967-020-02339-3","keywords":["acute respiratory distress syndrome (ards)","covid-19","il-6","inflammatory storm","sars-cov-2","tocilizumab"],"link_comment_in":"32290847","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["tocilizumab"],"_version_":1664636192640991234,"score":42.949093}]}